STOCK TITAN

Verve Therapeutics, Inc. - VERV STOCK NEWS

Welcome to our dedicated page for Verve Therapeutics news (Ticker: VERV), a resource for investors and traders seeking the latest updates and insights on Verve Therapeutics stock.

Company Overview

Verve Therapeutics, Inc. (VERV) is a clinical-stage biotechnology company focused on revolutionizing cardiovascular disease treatment through innovative genetic medicines. The company is dedicated to developing single-course gene editing therapies aimed at permanently lowering low‐density lipoprotein cholesterol (LDL‐C) and triglyceride levels, which are critical drivers of atherosclerotic cardiovascular disease. By harnessing breakthroughs in human genetics and advanced gene editing technologies, Verve Therapeutics is reshaping the paradigm from chronic management to one‐time interventions that offer lasting benefits.

Innovative Therapeutic Approach

At the core of Verve Therapeutics is its pioneering use of adenine base editing, delivered via specially engineered lipid nanoparticles. This approach enables precise targeting of liver cells to inactivate specific genes responsible for elevated cholesterol levels. The technology is designed to offer durable outcomes through a single course of treatment, reducing or even eliminating the chronic dependence on existing therapies. Keywords such as gene editing, cardiovascular disease, and genetic medicines are integral components in communicating its innovative value proposition.

Clinical Pipeline and Programs

Verve Therapeutics is advancing a robust pipeline of investigational therapies that address significant unmet needs in cardiovascular care:

  • PCSK9 Program: The company is developing gene editing candidates that permanently inactivate the PCSK9 gene in the liver, which plays a critical role in cholesterol metabolism. Clinical trials are targeting patients with heterozygous familial hypercholesterolemia (HeFH) and those with established atherosclerotic cardiovascular disease (ASCVD) who experience persistently high LDL‐C levels.
  • ANGPTL3 Program: Aimed at patients with refractory hypercholesterolemia, this program targets the ANGPTL3 gene. It represents a strategic venture into addressing conditions that remain inadequately managed by traditional treatments.
  • LPA Program: In collaboration with key industry partners, Verve Therapeutics is exploring gene editing strategies targeting the LPA gene, a well‐validated and independent risk factor for a range of cardiovascular conditions.

Research and Development Excellence

Verve’s approach is distinguished by its strong commitment to scientific rigor and robust research and development. The company’s comprehensive R&D framework encompasses preclinical evaluation, ongoing clinical trials, and extensive regulatory engagement. Its transparent reporting of trial endpoints, safety data, and collaborative initiatives with industry-leading partners further bolsters its reputation for expertise and authoritativeness in the competitive biotech landscape.

Market Position and Industry Landscape

In an industry frequently dominated by chronic care models, Verve Therapeutics occupies a unique niche by offering one-time treatments that have the potential for lifelong benefits. This disruptive model not only promises to improve patient adherence and quality of life but also positions the company at the forefront of a rapidly evolving therapeutic market. Despite inherent challenges, the company’s detailed clinical trial designs and rigorous safety assessments demonstrate its capability to navigate complex regulatory environments and competitive pressures.

Commitment to Patient Safety and Clinical Excellence

Patient safety is of paramount importance at Verve Therapeutics. The design and execution of its clinical trials incorporate stringent safety protocols and continuous monitoring of adverse events. By aligning its development strategies with regulatory best practices and maintaining high transparency in clinical reporting, the company instills confidence in both the medical community and investors regarding the long-term viability of its therapies.

Conclusion

Verve Therapeutics, Inc. is shaping a new future in cardiovascular treatment with its cutting-edge gene editing medicines. Its focused approach on permanently lowering cholesterol through targeted genetic interventions underlines a transformative vision that could redefine standards of care across the industry. With a strategic pipeline, a strong foundation in R&D, and an unwavering commitment to clinical excellence, Verve Therapeutics stands as a pivotal company for understanding the next frontier in genetic medicine and cardiovascular therapy.

Rhea-AI Summary
Verve Therapeutics, Inc. (Nasdaq: VERV) announced the pricing of an underwritten public offering of 12,500,000 shares of its common stock at a public offering price of $10.00 per share, for total gross proceeds of $125.0 million. In addition, Verve has agreed to sell 2,296,317 shares of its common stock to Eli Lilly and Company in a private placement, resulting in aggregate gross proceeds of approximately $148.0 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.12%
Tags
-
Rhea-AI Summary
Verve Therapeutics, Inc. (Nasdaq: VERV) has commenced an underwritten public offering of shares of its common stock and intends to sell up to $35 million of its common stock to Eli Lilly and Company in a private placement. The company also plans to grant the underwriters a 30-day option to purchase additional shares. Jefferies, Guggenheim Securities, William Blair, BMO Capital Markets, and RBC Capital Markets are acting as joint book-running managers for the public offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.12%
Tags
-
Rhea-AI Summary
Verve Therapeutics, Inc.: First human proof-of-concept data for in vivo base editing from the ongoing heart-1 phase 1b clinical trial of VERVE-101 revealed LDL-C reductions of up to 55% and blood PCSK9 protein reductions of up to 84%. The safety profile supports continued development of VERVE-101, with enrollment ongoing in the 0.45 mg/kg and 0.6 mg/kg cohorts and plans to initiate an expansion cohort in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Verve Therapeutics, Inc. has made significant progress in developing single-course gene editing medicines for cardiovascular disease, with FDA clearing its Investigational New Drug Application for VERVE-101 in HeFH patients. Verve also announced an expanded collaboration with Eli Lilly and Company and the acquisition of product rights to Verve's PCSK9 and ANGPTL3 programs. The company reported $485.2 million in cash, cash equivalents, and marketable securities, ensuring cash runway into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
24.83%
Tags
-
Rhea-AI Summary
Verve Therapeutics has announced that Eli Lilly and Company (Lilly) has acquired certain product rights to Verve's cardiovascular gene editing programs from Beam Therapeutics. The product candidates are designed to lower low-density lipoprotein cholesterol in patients with or at risk for cardiovascular disease. Lilly now holds the product rights previously held by Beam, including the right to opt-in to share development expenses and to jointly commercialize the products in the United States. Verve retains control of development and commercialization outside the United States.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
27.95%
Tags
none
-
Rhea-AI Summary
Verve Therapeutics receives FDA clearance to conduct clinical trial for cardiovascular disease treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.19%
Tags
none
Rhea-AI Summary
Verve Therapeutics to present interim data from its heart-1 Phase 1b clinical trial of VERVE-101 at AHA Scientific Sessions 2023. VERVE-101 aims to reduce LDL cholesterol. Investor event to be held on November 12, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.75%
Tags
conferences clinical trial
-
Rhea-AI Summary
Verve Therapeutics CEO to participate in fireside chat at Cantor Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.89%
Tags
conferences
-
Rhea-AI Summary
Verve Therapeutics appoints Fred Fiedorek as CMO, Andrew Bellinger transitions to CSO
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.24%
Tags
management
Rhea-AI Summary
Verve Therapeutics, Inc. reported recent company progress and financial results for the second quarter of 2023. Their primary focus is on developing medicines targeting three pillars of cardiovascular risk: low-density lipoproteins (LDL), triglyceride-rich lipoproteins (TRL) and lipoprotein(a) (Lp(a)). They are expecting to report initial clinical data from the heart-1 Phase 1b clinical trial of VERVE-101 in the fourth quarter of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.68%
Tags

FAQ

What is the current stock price of Verve Therapeutics (VERV)?

The current stock price of Verve Therapeutics (VERV) is $3.845 as of April 3, 2025.

What is the market cap of Verve Therapeutics (VERV)?

The market cap of Verve Therapeutics (VERV) is approximately 335.2M.

What is the primary focus of Verve Therapeutics?

Verve Therapeutics is dedicated to developing single-course gene editing therapies aimed at permanently lowering cholesterol levels to combat cardiovascular disease.

Which genes are targeted by Verve Therapeutics' treatments?

The company targets key genes such as PCSK9, ANGPTL3, and LPA, all of which play crucial roles in regulating cholesterol and influencing cardiovascular risk.

How does Verve's approach differ from traditional cardiovascular treatments?

Unlike traditional chronic therapies, Verve's one-time gene editing treatments are designed to provide lasting benefit by permanently altering genetic expression, thereby reducing the need for ongoing medication.

What clinical trials are currently underway at Verve Therapeutics?

Verve is conducting Phase 1b clinical trials for its PCSK9 and ANGPTL3 programs, focusing on evaluating safety, tolerability, and efficacy in patients with high LDL cholesterol levels.

What innovative technologies does Verve utilize in its therapies?

Verve employs an adenine base editing system along with proprietary lipid nanoparticle delivery to precisely target liver cells for gene inactivation, ensuring a controlled and lasting therapeutic effect.

Who can benefit from Verve Therapeutics' treatments?

Patients with conditions such as heterozygous familial hypercholesterolemia (HeFH) and those with atherosclerotic cardiovascular disease (ASCVD) who suffer from persistently high LDL levels may benefit from these innovative treatments.

How does the company ensure safety in its gene editing therapies?

Verve implements rigorous clinical protocols, continuous monitoring, and stringent regulatory compliance throughout its trials to ensure that safety standards are met and maintained.

What distinguishes Verve Therapeutics in the biotechnology sector?

Its focus on one-time, permanent gene editing treatments for cardiovascular disease, backed by cutting-edge technology and robust R&D, sets Verve apart from traditional chronic management therapies.
Verve Therapeutics, Inc.

Nasdaq:VERV

VERV Rankings

VERV Stock Data

335.20M
84.27M
5.04%
90.12%
16.74%
Biotechnology
Pharmaceutical Preparations
Link
United States
BOSTON